| Cell line name |
LoVo_6244R |
|---|
| Synonyms |
L6244-R |
|---|
| Accession |
CVCL_C3GL |
|---|
| Resource Identification Initiative |
To cite this cell line use: LoVo_6244R (RRID:CVCL_C3GL) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_90227; Selumetinib (AZD6244).
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Colon adenocarcinoma (NCIt: C4349) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0399 (LoVo) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
56Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=31048689; DOI=10.1038/s41467-019-09438-w; PMCID=PMC6497655
Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K., McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G., Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J., Saez-Rodriguez J., Smith P.D., Cook S.J.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance.
Nat. Commun. 10:2030.1-2030.22(2019) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C3GL
|
|---|
| Encyclopedic resources |
Wikidata; Q114311891
|
|---|
| Gene expression databases |
GEO; GSM3591766
|
|---|
| Entry history |
|---|
| Entry creation | 22-Sep-2022 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
